LDL lowering versus LDL eradication; what makes clinical sense ?
Prof. Kastelein discusses whether LDL-c eradication makes more sense than LDL-c lowering, based on the latest scientific insights.
Video navigation menu
- LDL-c: from hypothesis to axioma 01:39
- How low can we go with LDL-c? 02:54
- LDL-c reduction: earlier is better 04:20
- What are the pitfalls of treatment allocation? 06:38
- Looking ahead: anything to improve? 08:32
This lecture by prof. John Kastelein was part of a CME accredited symposium: "New concepts and models in CV risk management" held at ESC 2018 in Munich, Germany.
Prof. John Kastelein, MD – Professor of Medicine, Department of Vascular Medicine at the Amsterdam University Medical Centers (AUMC) of the University of Amsterdam, The Netherlands, where he holds the Strategic Chair of Genetics of Cardiovascular Disease
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from Pfizer.